Haematologica, Vol 92, Issue 11, 1495-1504 doi:10.3324/haematol.11448
Copyright © 2007 by Ferrata Storti Foundation

This Article Abstract Full Text (PDF) Alert me when this article is cited Alert me if a correction is posted Services Email this article to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Bäckman, E. Articles by Rosén, A. Search for Related Content PubMed PubMed Citation Articles by Bäckman, E. Articles by Rosén, A.

Chronic Lymphocytic Leukemia

Thioredoxin, produced by stromal cells retrieved from the lymph node microenvironment, rescues chronic lymphocytic leukemia cells from apoptosis in vitro

Eva Bäckman, Ann-Charlotte Bergh, Irena Lagerdahl, Björn Rydberg, Christer Sundström, Gerard Tobin, Richard Rosenquist, Mats Linderholm, Anders Rosén

From the Department of Experimental Medicine, Linköping University, SE-581 85 Linköping, Sweden (EB, AB, IL, BR, ML and AR); Department of Genetics and Pathology, Rudbeck Laboratory, Uppsala University, SE-751 85 Uppsala, Sweden (CS, GT, RR)

Correspondence: Eva Bäckman, Department of Experimental Medicine, Division of Cell Biology, Linköping University, SE-581 85 Linköping, Sweden. E-mail: eva.backman{at}ibk.liu.se/ anders.rosen{at}ibk.liu.se

TOP ABSTRACT Design and Methods Results Discussion References

 
Background and Objectives: The redox-regulatory protein thioredoxin has several functions including transcriptional regulation, and antioxidant, cytokine, and chemokine activities. We have previously shown that extracellular thioredoxin protects B-cell chronic lymphocytic leukemia (CLL) cells from apoptosis in vitro. In this study we were interested to determine whether thioredoxin is produced by cells surrounding the CLL cells in the in vivo microenvironment and whether this cell-derived thioredoxin has any leukemia growth-promoting effect in vitro.

Design and Methods: Lymph nodes from CLL patients (n=25) were analyzed for thioredoxin expression by immunohistology. Stromal cells purified from the lymph nodes were analyzed for thioredoxin secretion at the single cell level using an ELIspot assay. The survival effect of the stromal-derived thioredoxin was tested by co-culturing stromal- and CLL cells with and without Fab-fragments of an anti-thioredoxin antibody.

Results: The results indicated that the thioredoxin production correlated with the amount of proliferating cells and was mainly localized to the proliferation centers (pseudofollicles) in the CLL lymph nodes. The leukemia cells per se showed minimal thioredoxin levels; in contrast, stromal cells strongly expressed thioredoxin. Purified primary stromal cells, which secreted extracellular thioredoxin, significantly protected the CLL cells from undergoing apoptosis in 72 h co-cultures. Interestingly, this anti-apoptotic effect could be abrogated by addition of Fab-fragments of an anti- thioredoxin antibody.

Interpretation and Conclusions: In conclusion, we have shown that stromal cells in the lymph node microenvironment produce thioredoxin and that the thioredoxin production is localized to the proliferation centers of the CLL lymph nodes. In addition, thioredoxin produced by purified stromal cells rescued CLL cells from apoptosis in vitro.

Key words: CLL, thioredoxin, stromal cells, microenvironment.

B-cell chronic lymphocytic leukemia (CLL) is characterized by increasing high numbers of long-lived, monoclonal CD5⁺ B cells in bone marrow, blood and secondary lymphoid tissue.¹ Nowadays, it is generally accepted that the resistance to programmed cell death and the selective survival advantage of CLL cells is not only an autonomous characteristic, but depends on external anti-apoptotic stimuli. This is supported by the fact that despite their longevity in vivo, CLL cells often undergo spontaneous apoptosis under in vitro growth conditions. This also implies that in vitro cultured CLL cells lack essential survival signals that are present in the in vivo microenvironment.

Although the CLL cells in the blood are regarded as non-dividing, a small fraction of CLL cells replicate in proliferation centers (pseudofollicles) in bone marrow and lymph nodes.^2,3 Recently, it was shown that the birth rate of CLL cells varies from 0.1% to greater than 1% per clone and day.⁴ In addition, several cases of CLL with atypical morphological features in the bone marrow have, besides quiescent and proliferating cells, also subpopulations of CLL cells that undergo spontaneous apoptosis.⁵ This implies that the disease process is more dynamic than previously considered and that it is characterized by proliferating as well as dying cells. Selected microenvironmental signals delivered by accessory cells, such as bone marrow stromal cells and T cells appear to confer CLL cells with a growth advantage and extended survival.^6,7 To further identify important growth-promoting molecular interactions, this study focused on the redox-active thioredoxin protein. Thioredoxin is a multifunctional protein, ubiquitously expressed at a low level in all cells of the body. Intra-cellular thioredoxin has anti-apoptotic as well as growth-promoting effects and additionally, some types of cells have the capacity to release thioredoxin. This extracellular form of thioredoxin has cytokine and chemokine activities.⁸ Interestingly, exogenous thioredoxin was previously shown to protect malignant CLL cells from apoptosis in vitro.⁹

In this study, the potential in vivo role of thioredoxin was addressed by analyzing this protein’s expression in CLL lymph nodes. Furthermore, lymph node-derived stromal cells including fibroblastic reticular cells (FRC) and follicular dendritic cells (FDC) were isolated and analyzed for thioredoxin secretion and the ability to protect CLL cells from apoptosis.

TOP ABSTRACT Design and Methods Results Discussion References

 
Patients’ samples
This study was approved by the ethical committe of Linköping University (no. 00-111 and no. M30-05). Lymph nodes were collected from 13 patients with CLL (ID-1 to ID-13) and peripheral blood was collected from five CLL patients (ID-11; ID-13 to ID-16). The CLL patients were selected among consecutively attending patients at the Haematology Clinic, University Hospital, Linköping, Sweden. In addition, lymph node sections from 12 CLL patients (ID-17 to ID28) were collected at the Department of Pathology, Uppsala University Hospital, Uppsala, Sweden. Morphologic classification was performed according to the World Health Organization (WHO) classification and the tumors typically expressed CD5, CD23 and showed weak expression of Ig. Table 1 shows the clinical characteristics of the patients. Their IGHV mutational status and CD38 expression have been published previously.^10,11 Control tonsils were retrieved from children undergoing tonsillectomy because of sleeping problems.

View this table: [in this window] [in a new window] [Download PPT slide]

Table 1. Clinical characteristics of the CLL patients.

Immunohistology
Formalin-fixed, paraffin-embedded sections from ten CLL lymph nodes (ID-1 to ID-10) and control lymph nodes (tonsils) were analyzed by immunohistochemistry. The tissues were submerged in 0.01 M Tris-EDTA, pH 9 at 94^oC for 30 min for antigen retrieval and thereafter stained with the antibodies described in Table 2. Mayer’s hematoxylin (Histolab, Göteborg, Sweden) was used for counterstaining and Mount Quick Aqueous (Histolab) for mounting. A Nikon microscope ECLIPSE E600W and Nikon digital camera DXM1200F together with the ACT-1 application program were used for imaging (Nikon, Badhoevedorp, The Netherlands). For subsequent analyses Adobe Photoshop CS2 9.0 software was applied (Adobe Systems, Mountain View, CA, USA).

View this table: [in this window] [in a new window] [Download PPT slide]

Table 2. Summary of antibodies used for immunohistology and flow cytometry.

For immunofluorescence 15 CLL lymph nodes (ID-11 to ID-13 and ID-17 to ID-28) were snap-frozen in pre-cooled isopentane and stored at –80ºC until sectioning. Cryostat sections of 6 µm were sliced and placed on room temperature glass slides. The slides were then allowed to dry for at least 1 h at room temperature before fixation in acetone for 10 min and then dried for 15 min at room temperature. The tissues were incubated with the antibodies described in Table 2. SlowFade Gold mounting medium with DAPI (Molecular Probes) was used for mounting. A Zeiss Axiovert 200M inverted microscope, equipped with an AxioCam MRm camera and a Carl Zeiss 63x, N.A. 1.2, water objective, was employed for image acquisition (Brattleboro, VT, USA). Images were collected and analyzed using Zeiss AxioVision version 3.1 software. For subsequent analyses Adobe Photoshop version CS2 9.0 software was used (Adobe Systems, Mountain View, CA, USA). To study correlations, the stained area of the tissue sections stained for Ki-67, thioredoxin and FDC was quantified, using the Image J 1.37v image analyzing program from the NIH, as a proportion of the total area. Mean values are based on measurements from three to six fields for each patient, depending on the size of the lymph node sections To analyze thioredoxin secretion from purified accessory stromal cells, cells were seeded onto glass slides and incubated at 37°C in humidified air containing 5% CO2. The cells were fixed in 4% ice cold paraformaldehyde for 5 min and treated with 0.1% saponin for permeabilization. Thereafter, the cells were stained using the same procedure as for the lymph nodes tissues.

Cell purification and phenotype analysis
The cells used in this study were cultured in RPMI 1640 medium supplemented with 45 µg/mL penicillin, 45 µg/mL streptomycin, 1.8 mM L-glutamine and 10% fetal bovine serum (FBS) (Gibco, Paisley, Scotland) and grown at 37°C in humidified air containing 5% CO2. Peripheral blood mononuclear cells (PBMC) were purified from blood of CLL patients by centrifugation over a Ficoll-Hypaque density gradient medium (Amersham Pharmacia Biotech, Uppsala, Sweden). All CLL PBMC samples examined contained more than 90% of CLL cells as determined by flow cytometry with anti-CD5-RPE and anti-CD19-RPE-Cy5. Stromal cells including FRC and FDC were purified from CLL lymph nodes (ID-11 to ID-13) and tonsil tissue. Single cell suspensions were retrieved after mincing the lymph nodes and tonsils in a stainless steel mesh. The cells were seeded in tissue flasks and adherent cells were fed every fourth day by replacing 50% of the medium until confluence. The phenotype of the adherent cells was analyzed by flow cytometry using the antibodies described in Table 2. Goat (F(ab’)₂) anti-mouse Ig-F (Dako) was used as the secondary reagent for detection of unconjugated antibodies. Flow cytometric analysis was performed on a FACS Calibur Flow Cytometer equipped with CellQuest-Pro research software (Becton Dickinson).

ELISpot and ELISA
The ELISpot assay was performed according to Sahaf et al.¹² using the goat anti-thioredoxin polyclonal antibody (A.R.) to coat PVDF-bottomed 96-well microtiter plates (Millipore, Bedford, MA, USA). The biotinylated anti-thioredoxin monoclonal antibody (clone 2G11, IMCO Corporation Ltd. AB, USA) was used as the secondary (detector) antibody. The monocytes used as the positive control were purified as previously described.¹² One hundred thousand stromal cells or monocytes were added per well. The number of spots was counted blindly and independently in a Nikon stereo microscope (35x magnification) by two people. The enzyme linked immunosorbent assay (ELISA) was performed according to Söderberg et al.¹³ using anti-thioredoxin monoclonal antibody (clone 2G11) as the capture antibody and goat anti-thioredoxin-biotinylated (A.R.) as the indicator antibody.

Survival assay
Stromal cells purified from normal tonsil and CLL lymph nodes were seeded separately in 96-well plates (Corning Inc. NY, NY, USA) at a cell density of 5x10³ cells/well in R10 medium. The stromal cells were cultured at 37°C in a 5% CO2 humidified atmosphere for 24 h. Thereafter, the medium was aspirated from the adherent cells and CLL cells were added to the plates at a cell density of 2.5x10⁵ cells/well in RPMI supplemented with 45 U/mL penicillin, 45 µg/mL streptomycin, 1.8 mM L-glutamine and 1% FBS (Gibco) in the presence or absence of Fab fragments of anti-thioredoxin (clone 2G11) or control Fab fragments of mouse IgG (Jackson ImmunoResearch Laboratories, Baltimore, PA, USA). Fab fragments of anti- thioredoxin were produced using the ImmunoPure Fab preparation kit (Piece, Rockford, USA). As a control, CLL cells alone were used. After co-culturing for 72 h the cells were harvested, and the viability (annexin V-fluoroscein isothiocyanate negative) of the tumor cells (CD5⁺CD19⁺) was analyzed by flow cytometry. Flow cytometric analyses were performed on a Calibur Flow Cytometer equipped with CellQuest-Pro (Becton Dickinson). The viability of the CLL cells was at least 90% at the start of the experiments.

Statistics
Statistical analyses were performed using Student’s t-test in Microsoft Excel and Pearson’s correlation in GraphPad Prism version 4.00 for Windows. p values <0.05 were considered statistically significant.

TOP ABSTRACT Design and Methods Results Discussion References

 
Thioredoxin expression in CLL lymph nodes and tonsils
Our previous study on the role of thioredoxin and its anti-apoptotic effect on CLL tumor cells in vitro was extended in this study by analyses of thioredoxin expression in sections of lymph nodes from CLL patients. Thioredoxin was expressed in all lymph nodes specimens although the intensity and frequency of positive cells varied (Figure 1). Low thioredoxin expression could be detected in the CLL tumor cells per se. In contrast, thioredoxin was highly expressed in cells with macrophage- or fibroblast-/dendritic-like morphology. To analyze thioredoxin expression in control lymphoid tissue, tonsil sections from tonsillectomized children were stained for thioredoxin. Fibroblast/dendritic-like cells outside the follicles of the cortex and dendritic-/macrophage-like cells inside the follicles showed thioredoxin expression that was significantly stronger than elsewhere in tonsils. The sections were negative for the isotype control mouse IgG (data not shown).

View larger version (116K): [in this window] [in a new window] [Download PPT slide]

Figure 1. Immunohistochemical detection of thioredoxin and Ki-67 in lymph nodes from CLL patients. Thioredoxin localization in ten different CLL lymph nodes (patient ID-1 to ID-10) and a tonsil section is shown. In single staining thioredoxin was detected with the 2G11 monoclonal antibody, anti-mouse Ig-HRP and DAB. Magnification 600x. Thioredoxin expression in tonsil is shown at 600x magnification as well as at 100x magnification. Double staining of thioredoxin and Ki-67 is shown (at 40x and 600x magnification) in the bottom row. For double staining the tissue was first incubated with Ki-67 monoclonal antibody (clone MIB-1) and developed with Envision AP. Thereafter the tissue was blocked with 5% mouse and 5% rabbit serum before anti- thioredoxin-FITC, HRP-conjugated anti-FITC was added. Fast Red was used as the AP substrate and DAB as the HRP substrate. Mayer’s hematoxylin was used for counterstaining

Fibroblast reticular cells and follicular dendritic cells overexpressed thioredoxin
In order to identify which cell type(s) were thioredox-in positive in CLL lymph nodes, we applied markers for FRC, FDC, macrophages, T cells and B cells. Thioredoxin was analyzed in frozen lymph node tissue sections from 15 CLL patients (ID-11 to ID-28) by double immunofluorescence using anti-thioredoxin and cell-type specific monoclonal antibodies. The results showed that FRC and FDC, representing stromal cells, expressed thioredoxin strongly (Figure 2A-F), whereas CLL cells and T cells had minimal levels of thioredoxin (Figure 2J-O). Some of the macrophages were also positive for thioredoxin expression (Figure 2G-I). The iso-type controls mouse IgG and mouse IgM were negative (Figure 2P-Q).

View larger version (79K): [in this window] [in a new window] [Download PPT slide]

Figure 2. Thioredoxin localization in FRC and FDC from frozen CLL lymph nodes sections. Anti-FDC was developed with Alexa594-conjugated anti-mouse IgM and the staining thus shows as red (A). Co-localization of anti-FDC and thioredoxin is shown as yellow. (B). Biotin-conjugated mouse anti-thioredoxin and Alexa488-conjugated-Streptavidin is shown as green. (C). Anti-FRC (mouse IgG1, clone d-7FIB), anti-CD68 (IgG1) and anti-CD19 (IgG1) was developed with Alexa488-conjugated anti-mouse IgG, F(ab’)2 and the staining is thus shown as green (D, G and J, respectively). Alexa594-conjugated anti-thioredoxin staining is shown as red (E, H and K). Co-localization of the FRC, CD68 and CD19 markers and thioredoxin is shown as yellow (F, I and L, respectively). Anti-CD3-FITC staining is shown as green (M) and Alexa594-conjugated anti- thioredoxin staining in red (N). Double staining is shown in O. The isotype controls mouse IgM together with Alexa594-conjugated goat anti-mouse IgM (P) and mouse IgG together with Alexa488-conjugated goat anti-mouse IgG, F(ab’)2 (Q) is also shown. 630x magnification. Immunofluorescence staining of a sample from one representative CLL patient (ID-12) out of three (ID-11 to ID-13) is shown.

The expression of thioredoxin correlated with the expression of Ki-67 and FDC
To determine whether the expression of thioredoxin correlated with the expression of Ki-67 (a nuclear proliferation associated protein, absent in resting G0 cells) and the presence of FDC, lymph nodes from 12 CLL patients (ID-17 to ID-28) were analyzed by immunofluorescence. The mean value (from three to six fields/patient) of the percentage thioredoxin stained area was compared with the mean value (from three to six fields/patient) of the percentage Ki-67 stained area. The results showed that expression of thioredoxin correlated with the expression of Ki-67 (Figure 3A). In addition, in those patients with a high proportion of proliferating cells (Ki-67⁺) the thioredoxin expression was mainly localized to the proliferation centers (Figure 1, lowest panel). The Ki-67⁺ cells in the proliferating centers were confirmed to be mainly CD5⁺CD19⁺ leukemic cells (data not shown). The thioredoxin expression also correlated with the presence of FDC (Figure 3B) and, as shown in Figure 2A-C, the thioredoxin expression was co-localized to the FDC. There was no significant difference in thioredoxin expression between unmutated cases and mutated cases (p=0.16) or between CD38⁺ and CD38^–cases (p=0.18). Because ten of the 12 patients had stage I CLL the correlation of thioredoxin with Rai stage was not analyzed.

View larger version (18K): [in this window] [in a new window] [Download PPT slide]

Figure 3. The overall thioredoxin expression in CLL lymph nodes correlated with the expression of FDC and Ki-67. The expression of thioredoxin and proliferating cells (Ki-67) was analyzed by single color immunofluorescence on successive sections as stained area as a proportion of the total area (A). Mean values from three to six fields/patient is shown (A). The expression of thioredoxin and FDC was analyzed by two color immunofluorescence on the same section (B). The mean values from three to six fields for each patient are shown (B). Pearson’s correlation test was used for statistical analysis of the results from 12 patients (ID-17 to ID-28).

Stromal cell-derived thioredoxin rescued CLL cells from apoptosis
Adherent cells with fibroblast-/dendritic-like morphology were purified from tonsils or CLL lymph nodes and phenotyped by flow cytometry. CD5 and CD19 were not expressed by the purified adherent cells excluding T- and B-cells (Figure 4 and Table 3). Furthermore, none of the cells expressed CD14, HLA-DR, -DP, -DQ or DC-LAMP, indicating absence of monocytes/macrophages and interdigitating dendritic cells (Figure 4 and Table 3). More than 90% of the adherent cells from CLL lymph nodes, as well as from tonsils, expressed CD44 and the fibroblastic marker d-7FIB (Figure 4 and Table 3). Stromal cells from tonsil and/or bone marrow have previously been shown to express CD44 and the fibroblastic marker.^{14, 15} A subpopulation of the cells from the tonsil as well as the CLL lymph nodes expressed CD40 and the FDC marker CNA.42 (Figure 4 and Table 3). Thus, the fibroblast-/dendritic-cell morphology and the presence of fibroblastic and FDC markers revealed the cells to be stromal cells including FRC and FDC. The stromal cells were analyzed for expression and secretion of thioredoxin by immunofluorescence and ELISpot assay, respectively. For immunofluorescence, the cells were double-stained with anti-CD44 (both FRC and FDC were CD44⁺) and anti-thioredoxin monoclonal antibody. The results showed that all cells contained thioredoxin (Figure 5A). The ELISpot technique was used for detection of thioredoxin-secretion at the single cell level. As shown in Figure 5B, some of the stromal cells were potent thioredoxin-secretors. Monocytes from normal blood donors, previously shown to secrete thioredoxin,¹² were used as a positive control. No false positive spots were observed in controls for necrotic cell-release using detergentlyzed cells (Figure 5B). In contrast to small round spots generated by monocytes secreting thioredoxin, the spots generated by stromal cells were large, which reflects the morphology of fibroblast and dendritic cells (data not shown). In addition to the ELISpot assay, culture super-natants were analyzed in ELISA, confirming thioredoxin-secretion by the stromal cells in the range of 10–50 ng/mL/72 h/2.5x10⁵ cells. The ELISpot, ELISA and immunofluorescence assays are complementary since they measure slightly different aspects (level of response, dynamic range and intervals of concentration, etc.); ELISpot is better suited for low level responses.¹⁶ However, since all stromal cells expressed thioredoxin, but only a proportion of these cells secreted thioredoxin, it cannot be excluded that there is/are subpopulation(s) among the purified stromal cells that are responsible for the thioredoxin secretion.

View larger version (16K): [in this window] [in a new window] [Download PPT slide]

Figure 4. Stromal cell-like phenotype of the purified adherent cells from tonsils and CLL lymph nodes. Adherent cells purified from tonsils (A) or CLL lymph nodes (B) were stained with anti-CD5-F (clone DK23), anti-CD19-RPE (clone HD37), anti-CD40-F (clone 2C6), anti-CD14-RPE (clone TUK14), anti-CD44-F (B-F24), anti-DC-LAMP (clone 104.G4), anti-HLA-DR,DP,DQ (clone CR3/43), anti-fibroblast (clone d-7FIB), and anti-FDC (clone CNA.42). Goat (F(ab’)2) anti-mouse Ig-F was used to detect the unconjugated antibodies. Mouse IgG and mouse IgM were used as isotype controls. The percentages of positive cells are shown below the labeled axes. One representative experiment out of the three included in Table 3 is shown.

View this table: [in this window] [in a new window] [Download PPT slide]

Table 3. Phenotype of adherent cells purified from tonsils and CLL lymph nodes.*

View larger version (39K): [in this window] [in a new window] [Download PPT slide]

Figure 5. Thioredoxin secretion by stromal cells purified from lymph nodes (A). Isolated stromal cells were analyzed for thioredoxin expression by two-color immunofluorescence for CD44 and thioredoxin. Anti-CD44-FITC (clone B-F24) is shown as green. Alexa594-conjugated anti-thioredoxin (clone 2G11) staining is shown as red. Co-localization of CD44 and thioredoxin staining is shown as yellow. The magnification of the micrographs is a x630 (B). ELISpot assay (20 h) showing the number of thioredoxin-secreting cells per 105 cells represented by monocytes (stimulated with 300 ng/mL PMA/300 ng/mL iono-mycin), stromal cells (SC) and detergent-lyzed (Tween 20) SC. The diagram shows mean values ± SE from six replicate wells in one of four separate experiments.

To analyze whether isolated stromal cells, shown to secrete thioredoxin ex vivo, had any effect on CLL cell survival, leukemia cells were cultured with or without adherent stromal cells. We found that stromal cells, retrieved either from tonsils or CLL lymph nodes, significantly reduced the percentage of apoptotic tumor cells in 72 h co-cultures (p=0.006 and p=0.005, respectively) (Figure 6A). There was no difference in anti-apoptotic effect when co-cultures of CLL cells and autologous stromal cells were compared with co-cultures of CLL cells and stromal cells from different patients (data not shown). The stromal cells did not express MHC class II, thus making allogeneic responses unlikely. The frequency of apoptotic CLL cells after co-culture with stromal cells differed to some extent depending on the CLL donor. However, in all experiments performed, there was a significant increase of viable cells in co-cultures of CLL and stromal cells compared with cultures of CLL cells alone.

View larger version (20K): [in this window] [in a new window] [Download PPT slide]

Figure 6. Thioredoxin-mediated improvement of leukemic cell survival after co-culturing with stromal cells from CLL lymph nodes. Leukemia cells from the blood of CLL patients were cultured with and without stromal cells purified from tonsils (SC, Tonsil) or CLL lymph nodes (SC, CLL, LN) (A). In addition, leukemia cells were cultured with stromal cells from CLL lymph nodes (SC) in the presence or absence of anti-thioredoxin (Trx) Fab fragments (B and C). The frequency of annexin V+ cells among the CD5+CD19+ cells analyzed by flow cytometry was used to determine the frequency of apoptotic cells among the leukemia cells. The figures show the mean values from triplicate experiments ± SE. Student’s t-test was used for statistical analysis and p<0.05 was considered statistically significant. Results from two representative patients (ID-13 and ID-14) from five different B-CLL patients analyzed (ID-11, ID-13 to ID-16) are presented.

The addition of Fab fragments of an IgG anti- thioredoxin monoclonal antibody to the CLL and stromal cell co-cultures significantly abrogated the anti-apoptotic effect mediated by the stromal cells (p=0.0018) (Figure 6B and 7). This increase could not be blocked by Fab fragments of mouse control IgG (p=0.8206) (Figure 6B and 7). No significant effects on cell survival were recorded when anti- thioredoxin monoclonal antibody was added to CLL cells alone (p=0.0700) (Figure 6 and 7). The increase in frequency of apoptotic CLL cells was dependent on the concentration of the anti-thioredoxin Fab fragments (Figure 6C). As shown in Figure 6B, addition of 20 µg/mL anti-thioredoxin Fab fragments was sufficient to significantly block the improved survival of CLL cells mediated by the stromal cells.

View larger version (25K): [in this window] [in a new window] [Download PPT slide]

Figure 7. Percentage of annex-in-V positive cells among the CD5+CD19+ leukemic cells after co-culturing with stromal cells in the presence or absence of anti-thioredoxin Fab fragments. After 72 h co-culturing the leukemic cells were harvested and analyzed by flow cytometry. The cells from each group (CLL, CLL+anti-thioredoxin Fab, CLL+SC, CLL+SC+anti-thioredox-in Fab and CLL+mouse IgG Fab) were triple-stained with CD5-RPE (clone DK23), CD19-RPE-Cy5 (clone HD37) and annexin-V-FITC. In the second row the percentage of CD5+CD19+ cells among the harvested cells is shown. The third row shows the percentage of annexin V+ cells among the CD5+CD19+ cells (gate R1). One representative experiment out of the ones included in Figure 6B is shown.

TOP ABSTRACT Design and Methods Results Discussion References

 
In this study we have demonstrated the active release of thioredoxin from accessory cells in vivo and the functional effect on leukemia cell survival in vitro. Thioredoxin, which was previously shown to protect CLL cells from apoptosis in vitro,⁹ was expressed in the lymph nodes of CLL patients. Interestingly, the leukemia cells per se expressed minimal amounts of thioredoxin. This is in accordance with previous results showing that the intracellular thioredoxin level in ex vivo CLL cells from peripheral blood is low¹⁷ and increases only upon potent B-cell mitogenic stimulation. The thioredoxin production in CLL lymph nodes was, in contrast, mainly attributed to accessory stromal cells (FRC and FDC). The thioredoxin producing cells with stromal-like morphology were not restricted to CLL lymph nodes, but could also be found in sections of tonsils. T cells in the CLL microenvironment have been shown to inhibit apoptosis of CLL cells;⁶ however, although T cells were found to be potent producers of interferon- and interleukin-4 (Bäckman E. et al., unpublished data) we did not find any overexpression of thioredoxin in these cells.

Accessory cells such as stromal cells are present in proliferation centers of CLL lymphoid tissues^6,7 suggesting leukemia growth-supporting properties for these cells. Interestingly, in this study the expression of thioredoxin correlated with the presence of stromal cells as well as proliferating Ki-67⁺ leukemia cells. In this, as in other studies, the size and number of proliferation centers varied from patient to patient. In patients with a high proportion of proliferating cells (Ki-67⁺) the thioredoxin-expressing cells were mainly localized to and surrounded by Ki-67⁺ leukemia cells, indicating that thioredoxin is a potential tumor survival factor.

Attempts have recently been made to analyze tissue biopsies for prognostic markers.^3,18 ZAP-70 overexpres-sion has been correlated with the absence of somatic mutations of the IGHV genes thus suggesting that ZAP-70 is involved in a more aggressive disease process.¹⁸ In this study, the expression of thioredoxin was not related to the mutated or unmutated status of IGHV genes. However, because few mutated cases were included, this may only imply that the potential leukemia growth-promoting effect mediated by thioredoxin is independent of the IGHV mutational status of the CLL patient.

In addition to the high expression of thioredoxin in stromal cells of CLL lymph nodes, our results demonstrated that purified stromal cells were highly potent thioredoxin-secretors ex vivo. The functional significance of this finding was ascertained in experiments in which we co-cultured stromal cells with CLL cells and found a decrease in the frequency of apoptotic CLL cells. This effect was specifically blocked by Fab fragments of an anti-thioredoxin monoclonal antibody. Our present results add a novel aspect to previous findings, revealing extended survival of leukemic B cells in an in vitro bone marrow environment.^{19, 20} Nurse-like cells expanded in vitro from CLL blood samples have also been shown to deliver growth and survival signals via CD31/CD38 and plexin-B1/CD100 ligand interactions as well as via stromal-derived factor.^21,22 Interestingly, both stromal cells retrieved from CLL bone marrow and nurse-like cells were able to secrete thioredoxin (Bäckman E. et al., unpublished data), indicating that the thioredoxin secretion by lymph node stromal cells was not tissue-specific. In our study, we cannot exclude that other stromal derived factors, besides thioredoxin, contributed to the improved CLL cell survival. However, it is noteworthy that the stromal cell-mediated anti-apoptotic effect was significantly blocked by anti-thioredoxin. The detailed molecular mechanism behind the improved thioredoxin-mediated CLL survival remains to be elucidated. However, it is known that the multifunctional thioredoxin protein exerts several redox-regulatory functions and physically associates with a large number of target proteins, modulating their three-dimensional structure (and functions) by catalyzing thiol-disulfide exchange reactions.⁸ Interferon- and CD4 are cysteine-rich membrane receptors known to be redox modulated by extra-cellular thioredoxin.^{23, 24} Intracellularly, thioredoxin binds to apoptosis signal-regulated kinase-1 (ASK-1) regulating its activity.²⁵ In addition, the DNA binding of the NF-B p50 subunit is regulated by thioredoxin.²⁶ Thus, thioredoxin is a key protein in inducing synthesis of several cytokines, including interleukin-4, interferon- and tumor necrosis factor, which are known to exert survival effects on CLL.²⁷

In our study, we found that accessory cells produced thioredoxin, which is in contrast with reports on other leukemias, such as adult T-cell leukemia and solid tumors, in which the primary tumor cells per se over expressed thioredoxin.^8,28,29 However, regardless of source, an excess of thioredoxin favored enhanced survival and, in some studies, was associated with a poor prognosis for the patients.^30,31

Secretion of thioredoxin has previously been shown to play a role in the activation of normal lymphocytes. For example, it has been shown that thioredoxin, in synergy with certain cytokines and CD40-ligation, induced S-phase entry and mitosis in normal B cells.³² In addition, Angelini et al. have shown that T cells are dependent on the secretion of cysteine and thioredoxin by antigen-presenting dendritic cells for their activation.³³ Thus, we cannot exclude that thioredoxin produced by stromal cells from lymph nodes have a growth-promoting effect on normal B cells as well.

In conclusion, this study demonstrated high levels of thioredoxin in accessory stromal cells, including FRC and FDC, in lymph nodes from patients with B-CLL. In addition, the expression of thioredoxin was mainly localized to and surrounded by proliferating leukemic cells. A possible functional significance of the thioredoxin expression was shown in co-culture experiments by extended thioredoxin-dependent survival of leukemic cells under the influence of stromal cells isolated from lymph nodes. Our finding, which was limited to showing thioredoxin-dependent CLL survival in vitro, support future in vivo studies focusing on the role of thioredoxin as critical for leukemia growth-promoting properties in CLL patients.

 
we thank Drs. Bernt Boeryd, Claes Malm and Franz Rommel, and Ms Annika Persson for help with the clinical specimens from the patients with CLL. We also thank Simin Tahmasebpoor for help with sectioning the lymph node tissues

 
Funding: this work was supported by funding provided by the Östergötland County Cancer Research Fund and Swedish Cancer Society 3171-B04. GSD.

Authors’ contributions

EB designed and performed the research, analyzed the data and wrote the paper; AB performed the research, analyzed the data and wrote the paper; IL and BR performed the research and analyzed the data; GT performed the research, analyzed the data and directed the clinical data; CS, RR and ML diagnosed the patients, directed the patients’ material and their clinical data; AR initiated, designed and supervised the research and analyzed the data. All authors reviewed the manuscript critically for important intellectual content and approved the final version.

Conflicts of Interest

The authors reported no potential conflicts of interest.

Received for publication February 27, 2007. Accepted for publication September 1, 2007.

TOP ABSTRACT Design and Methods Results Discussion References

 

1. Chiorazzi N, Rai KR, Ferrarini M. Chronic lymphocytic leukemia. N Engl J Med 2005;352:804-15.[Free Full Text]
2. Rosati S, Kluin PM. Chronic lymphocytic leukaemia: a review of the immuno-architecture. Curr Top Mi-crobiol Immunol 2005;294:91-107.[Web of Science][Medline]
3. Soma LA, Craig FE, Swerdlow SH. The proliferation center microenvironment and prognostic markers in chronic lymphocytic leukemia/small lymphocytic lymphoma. Hum Pathol 2006;37:152-9.[CrossRef][Web of Science][Medline]
4. Messmer BT, Messmer D, Allen SL, Kolitz JE, Kudalkar P, Cesar D, et al. In vivo measurements document the dynamic cellular kinetics of chronic lymphocytic leukemia B cells. J Clin Invest 2005;115:755-64.[CrossRef][Web of Science][Medline]
5. Bueso-Ramos CE, Ferrajoli A, Me-deiros LJ, Keating MJ, Estrov Z. Aberrant morphology, proliferation, and apoptosis of B-cell chronic lymphocytic leukemia cells. Hematology 2004;9:279-86.[CrossRef][Medline]
6. Ghia P, Circosta P, Scielzo C, Vallario A, Camporeale A, Granziero L, et al. Differential effects on CLL cell survival exerted by different microenvironmental elements. Curr Top Microbiol Immunol 2005;294:135-45.[Web of Science][Medline]
7. Caligaris-Cappio F. Role of the microenvironment in chronic lymphocytic leukaemia. Br J Haematol 2003;123:380-8.[CrossRef][Web of Science][Medline]
8. Gromer S, Urig S, Becker K. The thioredoxin system: from science to clinic. Med Res Rev 2004;24:40-89.[CrossRef][Web of Science][Medline]
9. Nilsson J, Söderberg O, Nilsson K, Rosén A. Thioredoxin prolongs survival of B-type chronic lymphocytic leukemia cells. Blood 2000;95:1420-6.[Abstract/Free Full Text]
10. Tobin G, Thunberg U, Laurell A, Karlsson K, Aleskog A, Willander K, et al. Patients with chronic lymphocytic leukemia with mutated VH genes presenting with Binet stage B or C form a subgroup with a poor outcome. Haematologica 2005;90:465-9.[Abstract/Free Full Text]
11. Thunberg U, Johnson A, Roos G, Thorn I, Tobin G, Sällstrom J, et al. CD38 expression is a poor predictor for VH gene mutational status and prognosis in chronic lymphocytic leukemia. Blood 2001;97:1892-4.[Free Full Text]
12. Sahaf B, Söderberg A, Ekerfelt C, Paulie S, Rosén A. Enzyme-linked immunospot assay for detection of thioredoxin and thioredoxin reductase secretion from cells. Methods Enzymol 2002;353:22-35.[Web of Science][Medline]
13. Söderberg A, Sahaf B, Rosén A. Thioredoxin reductase, a redox-active selenoprotein, is secreted by normal and neoplastic cells: presence in human plasma. Cancer Res 2000;60:2281-9.[Abstract/Free Full Text]
14. Jones EA, English A, Kinsey SE, Straszynski L, Emery P, Ponchel F, et al. Optimization of a flow cytometry-based protocol for detection and phenotypic characterization of multipotent mesenchymal stromal cells from human bone marrow. Cytometry B Clin Cytom 2006;70:391-9.[Medline]
15. Lisignoli G, Monaco MC, Facchini A, Toneguzzi S, Cattini L, Hilbert DM, et al. In vitro cultured stromal cells from human tonsils display a distinct phenotype and induce B cell adhesion and proliferation. Eur J Immunol 1996;26:17-27.[Web of Science][Medline]
16. Anthony DD, Lehmann PV. T-cell epitope mapping using the ELISPOT approach. Methods 2003;29:260-9.[CrossRef][Web of Science][Medline]
17. Ericson ML, Hörling J, Wendel-Hansen V, Holmgren A, Rosén A. Secretion of thioredoxin after in vitro activation of human B cells. Lymphokine Cytokine Res 1992;11:201-7.[Web of Science][Medline]
18. Zanotti R, Ambrosetti A, Lestani M, Ghia P, Pattaro C, Remo A, et al. ZAP-70 expression, as detected by immunohistochemistry on bone marrow biopsies from early-phase CLL patients, is a strong adverse prognostic factor. Leukemia 2007;21:102-9.[CrossRef][Web of Science][Medline]
19. Kay NE, Shanafelt TD, Strege AK, Lee YK, Bone ND, Raza A. Bone biopsy derived marrow stromal elements rescue chronic lymphocytic leukemia B-cells from spontaneous and drug induced cell death and facilitates an "angiogenic switch". Leuk Res 2007;20:899-906.
20. Lagneaux L, Delforge A, De Bruyn C, Bernier M, Bron D. Adhesion to bone marrow stroma inhibits apoptosis of chronic lymphocytic leukemia cells. Leuk Lymphoma 1999;35:445-53.[Web of Science][Medline]
21. Deaglio S, Vaisitti T, Bergui L, Bonello L, Horenstein AL, Tamagnone L, et al. CD38 and CD100 lead a network of surface receptors relaying positive signals for B-CLL growth and survival. Blood 2005;105:3042-50.[Abstract/Free Full Text]
22. Burger JA, Tsukada N, Burger M, Zvaifler NJ, Dell’Aquila M, Kipps TJ. Blood-derived nurse-like cells protect chronic lymphocytic leukemia B cells from spontaneous apoptosis through stromal cell-derived factor-1. Blood 2000;96:2655-63.[Abstract/Free Full Text]
23. Fountoulakis M. Unfolding intermediates of the extracellular domain of the interferon gamma receptor. J Biol Chem 1992;267:7095-100.[Abstract/Free Full Text]
24. Matthias LJ, Hogg PJ. Redox control on the cell surface: implications for HIV-1 entry. Antioxid Redox Signal 2003;5:133-8.[CrossRef][Web of Science][Medline]
25. Saitoh M, Nishitoh H, Fujii M, Takeda K, Tobiume K, Sawada Y, et al. Mammalian thioredoxin is a direct inhibitor of apoptosis signal-regulating kinase (ASK) 1. Embo J 1998;17:2596-606.[CrossRef][Web of Science][Medline]
26. Schulze-Osthoff K, Schenk H, Dröge W. Effects of thioredoxin on activation of transcription factor NF-kB. Methods Enzymol 1995;252:253-64.[CrossRef][Web of Science][Medline]
27. Tangye SG, Raison RL. Human cyto-kines suppress apoptosis of leukaemic CD5+ B cells and preserve expression of bcl-2. Immunol Cell Biol 1997;75:127-35.[Medline]
28. Powis G, Mustacich D, Coon A. The role of the redox protein thioredox-in in cell growth and cancer. Free Radic Biol Med 2000;29:312-22.[CrossRef][Web of Science][Medline]
29. Burke-Gaffney A, Callister ME, Nakamura H. Thioredoxin: friend or foe in human disease? Trends Pharmacol Sci 2005;26:398-404.[CrossRef][Medline]
30. Kakolyris S, Giatromanolaki A, Koukourakis M, Powis G, Souglakos J, Sivridis E, et al. Thioredoxin expression is associated with lymph node status and prognosis in early operable non-small cell lung cancer. Clin Cancer Res 2001;7:3087-91.[Abstract/Free Full Text]
31. Raffel J, Bhattacharyya AK, Gallegos A, Cui H, Einspahr JG, Alberts DS, et al. Increased expression of thioredoxin-1 in human colorectal cancer is associated with decreased patient survival. J Lab Clin Med 2003;142:46-51.[CrossRef][Web of Science][Medline]
32. Rosen A, Lundman P, Carlsson M, Bhavani K, Srinivasa BR, Kjellstrom G, et al. A CD4+ T cell line-secreted factor, growth promoting for normal and leukemic B cells, identified as thioredoxin. Int Immunol 1995;7:625-33.[Abstract/Free Full Text]
33. Angelini G, Gardella S, Ardy M, Ciriolo MR, Filomeni G, Di Trapani G, et al. Antigen-presenting dendritic cells provide the reducing extra-cellular microenvironment required for T lymphocyte activation. Proc Natl Acad Sci USA 2002;99:1491-6.[Abstract/Free Full Text]

This article has been cited by other articles:

				S. Deaglio and F. Malavasi Chronic lymphocytic leukemia microenvironment: shifting the balance from apoptosis to proliferation Haematologica, June 1, 2009; 94(6): 752 - 756. [Full Text] [PDF]

				A. Lanemo Myhrinder, E. Hellqvist, E. Sidorova, A. Soderberg, H. Baxendale, C. Dahle, K. Willander, G. Tobin, E. Backman, O. Soderberg, et al. A new perspective: molecular motifs on oxidized LDL, apoptotic cells, and bacteria are targets for chronic lymphocytic leukemia antibodies Blood, April 1, 2008; 111(7): 3838 - 3848. [Abstract] [Full Text] [PDF]

This Article Abstract Full Text (PDF) Alert me when this article is cited Alert me if a correction is posted Services Email this article to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Bäckman, E. Articles by Rosén, A. Search for Related Content PubMed PubMed Citation Articles by Bäckman, E. Articles by Rosén, A.